The Cancer Survivors Network (CSN) is a peer support community for cancer patients, survivors, caregivers, families, and friends! CSN is a safe place to connect with others who share your interests and experiences.
Trifunctional Antibody Catumaxomab as treatment for PPC

LaundryQueen
CSN Member Posts: 676
Future Oncol. 2010 Sep;6(9):1387-94.
The trifunctional antibody catumaxomab in treatment of malignant ascites and peritoneal carcinomatosis.
Ströhlein MA, Heiss MM.
SourceDepartment of Abdominal, Vascular & Transplant Surgery, Cologne-Merheim Medical Center, University of Witten/Herdecke, Ostmerheimer Strasse 200, Cologne, Germany. stroehleinm@kliniken-koeln.de
Abstract
Peritoneal carcinomatosis remains an unsolved medical problem in modern oncologic treatment. Excruciating symptoms such as malignant ascites, ileus, nausea, vomiting, dyspnoea and pain deteriorate the quality of life for affected patients. There is still no effective standard treatment for peritoneal carcinomatosis.
The trifunctional antibody catumaxomab (antiepithelial cell adhesion molecule x anti-CD3) is able to direct T lymphocytes and Fcg-receptor-positive accessory cells to epithelial cell adhesion molecule-positive tumor cells. Intraperitoneal catumaxomab therapy was shown to be the first effective therapy against accumulation of malignant ascites in patients with peritoneal carcinomatosis of epithelial cancer, reducing the need of paracentesis and prolonging puncture-free survival.
This paper reviews the mode of action of catumaxomab and analyzes different fields of local immunotherapy in patients with peritoneal carcinomatosis. A summary of completed and ongoing studies is included. Catumaxomab is discussed to be an outstanding option for local control and therapy of peritoneal carcinomatosis, which could be an optimal modular therapy in addition to systemic chemotherapy and surgical tumor resection.
The trifunctional antibody catumaxomab in treatment of malignant ascites and peritoneal carcinomatosis.
Ströhlein MA, Heiss MM.
SourceDepartment of Abdominal, Vascular & Transplant Surgery, Cologne-Merheim Medical Center, University of Witten/Herdecke, Ostmerheimer Strasse 200, Cologne, Germany. stroehleinm@kliniken-koeln.de
Abstract
Peritoneal carcinomatosis remains an unsolved medical problem in modern oncologic treatment. Excruciating symptoms such as malignant ascites, ileus, nausea, vomiting, dyspnoea and pain deteriorate the quality of life for affected patients. There is still no effective standard treatment for peritoneal carcinomatosis.
The trifunctional antibody catumaxomab (antiepithelial cell adhesion molecule x anti-CD3) is able to direct T lymphocytes and Fcg-receptor-positive accessory cells to epithelial cell adhesion molecule-positive tumor cells. Intraperitoneal catumaxomab therapy was shown to be the first effective therapy against accumulation of malignant ascites in patients with peritoneal carcinomatosis of epithelial cancer, reducing the need of paracentesis and prolonging puncture-free survival.
This paper reviews the mode of action of catumaxomab and analyzes different fields of local immunotherapy in patients with peritoneal carcinomatosis. A summary of completed and ongoing studies is included. Catumaxomab is discussed to be an outstanding option for local control and therapy of peritoneal carcinomatosis, which could be an optimal modular therapy in addition to systemic chemotherapy and surgical tumor resection.
Comments
Discussion Boards
- All Discussion Boards
- 6 Cancer Survivors Network Information
- 6 Welcome to CSN
- 122.5K Cancer specific
- 2.8K Anal Cancer
- 456 Bladder Cancer
- 312 Bone Cancers
- 1.7K Brain Cancer
- 28.6K Breast Cancer
- 408 Childhood Cancers
- 27.9K Colorectal Cancer
- 4.6K Esophageal Cancer
- 1.2K Gynecological Cancers (other than ovarian and uterine)
- 13.1K Head and Neck Cancer
- 6.4K Kidney Cancer
- 681 Leukemia
- 803 Liver Cancer
- 4.2K Lung Cancer
- 5.1K Lymphoma (Hodgkin and Non-Hodgkin)
- 242 Multiple Myeloma
- 7.2K Ovarian Cancer
- 69 Pancreatic Cancer
- 493 Peritoneal Cancer
- 5.6K Prostate Cancer
- 1.2K Rare and Other Cancers
- 544 Sarcoma
- 743 Skin Cancer
- 659 Stomach Cancer
- 192 Testicular Cancer
- 1.5K Thyroid Cancer
- 5.9K Uterine/Endometrial Cancer
- 6.4K Lifestyle Discussion Boards